Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Aptevo Therapeutics Inc APVO

Healthcare Biotechnology
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. It has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. Its lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:APVO)

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Accesswire 11 hours ago

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

Accesswire 4 days ago

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

Accesswire 6 days ago

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Accesswire November 11, 2024

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Accesswire November 7, 2024

Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024

Accesswire October 29, 2024

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Accesswire September 18, 2024

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Accesswire September 16, 2024

Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Accesswire September 16, 2024
View More News ››

Opinion & Analysis (NDAQ:APVO)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:APVO)

Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 3

News; $APVO Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day...
whytestocks - July 17, 2024

Using technical analysis for this one.

Big buy for me at .46 cents per share,so glta and do your own due diligence,but the worst seems to be over for this company and its stock...
coolfooldumbguy - July 17, 2024

APVO......sold all this a.m into strength

Cha -Ching!!!!!!!
Iseneschal - May 2, 2024

APVO.....come on down!!!!!!!!!!!

Let this drop like a rock ; )
Iseneschal - April 15, 2024

APVO....N.L.O.D.....LoL

Sub 70 ? Probably
Iseneschal - April 15, 2024

RE:Why Aptevo Therapeutics Stock Is Cratering | Benzinga

I'd say The Maggot has to change the way he does RS's......people start to catch on to the way Mr. M works. Surprise the masses....
Iseneschal - April 12, 2024
View more Bullboard ››

NexTech3D.AI Corp.

NexTech3D.AI Corp.

NexTech3D.AI Corp. is a diversified augmented reality (AR), artificial intelligence (AI) technology company. The Company ...
View More »